Free Trial
TSE:FRX

Fennec Pharmaceuticals 3/21/2024 Earnings Report

Fennec Pharmaceuticals logo
C$11.38 +0.28 (+2.52%)
As of 11:01 AM Eastern

Fennec Pharmaceuticals EPS Results

Actual EPS
-C$0.14
Consensus EPS
C$0.02
Beat/Miss
Missed by -C$0.16
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
$13.25 million
Expected Revenue
$12.88 million
Beat/Miss
Beat by +$370.00 thousand
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Fennec Pharmaceuticals Earnings Headlines

HC Wainwright Analysts Boost Earnings Estimates for TSE:FRX
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Wedbush Lifts Earnings Estimates for Fennec Pharmaceuticals
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (TSE:FRX) operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat